AstraZeneca’s (AZ) Evusheld (tixagevimab and cilgavimab, formerly AZD7442) has been approved by the European Commission (EC) for the treatment of individuals with COVID-19, the company announced.
The approval is specifically for the treatment of adults and adolescents – aged 12 years and older weighing at least 40kg – with COVID-19 who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.
